Featured Publications
Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention
Seibert T, Garraway I, Plym A, Mahal B, Giri V, Jacobs M, Cheng H, Loeb S, Helfand B, Eeles R, Morgan T. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology 2023, 83: 241-248. PMID: 36609003, DOI: 10.1016/j.eururo.2022.12.021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTimes higher riskGenetic risk scoreHigh genetic risk scoreLethal prostate cancerProstate cancerHigh genetic riskHigh riskRare pathogenic mutationsHealthy lifestyleEarly detectionPCa riskRisk predictionHigh-grade prostate cancerGenetic riskAggressive prostate cancerProstate cancer riskGenetic risk assessmentDNA damage repair genesGenetic risk predictionPCa mortalityAggressive diseaseLeading causeFamily historyCancer riskElevated risk
2024
PD01-01 GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PROSTATE CANCER: RESULTS FROM THE TECHNOLOGY-ENHANCED ACCELERATION OF GERMLINE EVALUATION FOR THERAPY (TARGET) STUDY
Loeb S, Gross L, Cheng H, Rivera A, Keith S, Byrne N, Nolasco T, Giri V. PD01-01 GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PROSTATE CANCER: RESULTS FROM THE TECHNOLOGY-ENHANCED ACCELERATION OF GERMLINE EVALUATION FOR THERAPY (TARGET) STUDY. Journal Of Urology 2024, 211: e62. DOI: 10.1097/01.ju.0001009540.33579.43.01.Peer-Reviewed Original ResearchToward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer
Vandekerkhove G, Giri V, Halabi S, McNair C, Hamade K, Bitting R, Wyatt A. Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. JCO Precision Oncology 2024, 8: e2300654. PMID: 38547422, PMCID: PMC10994438, DOI: 10.1200/po.23.00654.Peer-Reviewed Original ResearchConceptsClinical genomic testingGenomic testingProstate cancerTumor tissuesPoly (ADP-ribose) polymerase inhibitorsPlasma cell-free DNAHereditary cancer implicationsLow tumor fractionAdvanced prostate cancerDNA damage repair genesHealth care professionalsCell-free DNANonpathogenic variantsPatient's germlineOptimal patient careSomatic alterationsSubclonal alterationsClinical decision makingClonal hematopoiesisCare professionalsGenotyping testPoor prognosisTumor fractionPatient careCancer managementTARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Loeb S, Keith S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Wise D, Hollifield L, Giri V. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precision Oncology 2024, 8: e2300552. PMID: 38452310, PMCID: PMC10939575, DOI: 10.1200/po.23.00552.Peer-Reviewed Original ResearchConceptsGermline genetic testingDecisional conflictGenetic counselingProstate cancerPatient-drivenShortage of genetic counselorsKnowledge of cancer geneticsHereditary cancer riskReduce decisional conflictDecisional Conflict ScalePrimary outcome dataMixed-effects regression modelsDiverse patient populationsGenetic servicesClinical trial eligibilityGenetic counselorsGenetics educationPatient experienceCancer riskGermline testingAnalytical data setsCancer geneticsGermline evaluationConflict ScaleGenetic testingAddressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board
Loeb S, Cheng H, Paller C, Weg E, Johnson J, Gross L, Keith S, Russo J, Hathaway F, Rivera A, Giri V. Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. Prostate Cancer And Prostatic Diseases 2024, 1-3. PMID: 38172199, DOI: 10.1038/s41391-023-00778-9.Peer-Reviewed Original Research
2023
Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.
Giri V, Keith S, Cheng H, Leader A, Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Loeb S. Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Journal Of Clinical Oncology 2023, 41: 10598-10598. DOI: 10.1200/jco.2023.41.16_suppl.10598.Peer-Reviewed Original ResearchDecisional conflictGenetic testingPre-test genetic counselingGermline testingGenetic counselingProstate cancerRandomized non-inferiority trialHereditary cancer risk assessmentGermline genetic testingClinical trial eligibilityNon-inferiority trialProstate Cancer FoundationProstate cancer managementCancer genetic testingDecision Conflict ScaleCancer risk assessmentGermline evaluationTrial eligibilityPrimary endpointMean ageStudy protocolCancer managementGenetics educationAnalysis of covarianceCancer FoundationA generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes
Ritch E, Herberts C, Warner E, Ng S, Kwan E, Bacon J, Bernales C, Schönlau E, Fonseca N, Giri V, Maurice-Dror C, Vandekerkhove G, Jones S, Chi K, Wyatt A. A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. Npj Precision Oncology 2023, 7: 27. PMID: 36914848, PMCID: PMC10011564, DOI: 10.1038/s41698-023-00366-z.Peer-Reviewed Original ResearchMetastatic prostate cancerDDR gene alterationsProstate cancerGene alterationsDDR deficiencyOngoing clinical trialsPlasma cell-free DNADNA damage repair defectsLiquid biopsy specimensMismatch repair deficiencyLeukocyte DNA samplesBladder cancer samplesCell-free DNABiopsy specimensBladder cancerClinical trialsTreatment benefitMetastatic prostateInherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).
Couvillon A, Turkbey B, Choyke P, Lee-Wisdom K, McKinney Y, Sidlow R, Mullane M, Giri V, Morgan T, Cheng H, Merino M, Figg W, Pinto P, Dahut W, Karzai F. Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI). Journal Of Clinical Oncology 2023, 41: 390-390. DOI: 10.1200/jco.2023.41.6_suppl.390.Peer-Reviewed Original ResearchGermline pathogenic variantsProstate cancerActive surveillancePathogenic variantsMedian ageRadiation therapyMonitoring of PCaDiagnosis of PCaDistinct pathogenic variantsHigh-risk geneticsPIRADS 3 lesionsPIRADS 4 lesionsISUP grade group 1Grade group 1Localized prostate cancerMonoallelic pathogenic variantsDNA mismatch repair genesLikely pathogenic variantsProstate cancer diagnosisMismatch repair genesDefinitive treatmentPSA monitoringProstate biopsyBiopsy specimensRisk factors
2022
Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer
Thakker S, Loeb S, Giri V, Bjurlin M, Matulewicz R. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer. Urology Practice 2022, 10: 26-32. PMID: 37103438, DOI: 10.1097/upj.0000000000000352.Peer-Reviewed Original ResearchConceptsBreast/ovarian cancerHealth Information National Trends Survey 5Ovarian cancerProstate cancerGenetic testingCancer historyGenetic testing informationHistory of cancerHealthy U.S. adultsExposure of interestHealth care professionalsSelf-reported ratesEvidence-based informationPatient populationRepresentative sampleCare professionalsPatientsSecondary objectiveU.S. adultsCancerCommon sourceCategorical variablesSurvey 5Lack of awarenessCycle 4Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families
Leader A, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri V. Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. Journal Of Community Genetics 2022, 13: 547-556. PMID: 35869324, PMCID: PMC9681950, DOI: 10.1007/s12687-022-00603-1.Peer-Reviewed Original ResearchGenetic test resultsProstate cancerGenetic testingDiagnosis of PCaFamily membersClinical trial optionsGermline genetic testingPV/LPVRelevant family membersGenetic testing experiencesImmediate family membersPCa patientsCancer screeningPatientsTrial optionsPrecision therapyGenetic resultsGenetic counselorsTesting experienceThematic analysisCommunication barriersSemi-structured interviewsParticipantsTherapyTestingTechnology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing
Loeb S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Wise D, Hollifield L, Brown L, Slater E, Pieczonka C, Gomella L, Kelly W, Trabulsi E, Handley N, Lallas C, Chandrasekar T, Mille P, Mann M, Mark J, Brown G, Chopra S, Wasserman J, Phillips J, Somers P, Giri V. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials 2022, 119: 106821. PMID: 35710085, DOI: 10.1016/j.cct.2022.106821.Peer-Reviewed Original ResearchConceptsKey patient-reported outcomesGermline testingPatient-reported outcomesProstate cancerGenetic counselingCollaborative care strategiesProstate cancer careTwo-armed randomizedProstate Cancer FoundationEducation/counselingGermline evaluationGOV IDENTIFIERPrimary outcomeSecondary outcomesStudy armsTarget enrollmentAshkenazi Jewish ancestryCancer careFamily historyTumor featuresCancer FoundationCare strategiesDecisional conflictUS sitesPractice settingsGermline testing and genetic counselling in prostate cancer
Russo J, Giri V. Germline testing and genetic counselling in prostate cancer. Nature Reviews Urology 2022, 19: 331-343. PMID: 35449224, PMCID: PMC9022414, DOI: 10.1038/s41585-022-00580-7.Peer-Reviewed Original ResearchConceptsProstate cancerCancer risk managementCancer riskGenetic testingHereditary cancer predisposition syndromesPre-test discussionUnique clinical featuresGermline pathogenic variantsPrecision medicineHealth care professionalsComplex management optionsAdditional cancer riskCancer predisposition syndromeHereditary cancer riskGenetic counsellingGermline testingMetastatic diseaseClinical featuresOptimal careMedical historyFamily historyPathogenic variantsPrecision therapyGene testingCancerGenetic testing in prostate cancer management: Considerations informing primary care
Giri V, Morgan T, Morris D, Berchuck J, Hyatt C, Taplin M. Genetic testing in prostate cancer management: Considerations informing primary care. CA A Cancer Journal For Clinicians 2022, 72: 360-371. PMID: 35201622, DOI: 10.3322/caac.21720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNational Comprehensive Cancer Network guidelinesProstate cancerPrimary careGenetic testingNetwork guidelinesFamily historyClinical trial optionsGermline genetic testingMetastatic prostate cancerPrimary care providersMultidisciplinary patient careProstate cancer managementRole of cliniciansHereditary cancer riskMultiple professional societiesComprehensive family historyPC survivorsGermline testingPC screeningAggressive diseasePoor outcomePC careClinical pathwayCancer managementCancer riskVirtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: The ENGAGEMENT study.
Giri V, Gross L, Cheng H, Russo J, Paller C, Johnson J, Weg E, Loeb S. Virtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: The ENGAGEMENT study. Journal Of Clinical Oncology 2022, 40: 184-184. DOI: 10.1200/jco.2022.40.6_suppl.184.Peer-Reviewed Original ResearchMetastatic prostate cancerProstate cancerGermline testingGenetic counselingRisk of PCaEarly-stage prostate cancerBaseline surveyHigh-risk diseaseStandard of careCancer genetic testingCancer genetics knowledgeMedical oncologistsMedical oncologyClinical trial managementClinical trialsNurse practitionersCancer managementAcademic centersFavorable responseCase discussionRadiation oncologistsPCa screeningKnowledge scoreGenetic testingPractice settingsPrevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study.
Giri V, Gross L, Russo J, Shimada A, McNair C, Kelly W, Gomella L. Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study. Journal Of Clinical Oncology 2022, 40: 188-188. DOI: 10.1200/jco.2022.40.6_suppl.188.Peer-Reviewed Original ResearchProstate cancerPrevalence of FAGermline testingEMPOWER studyMultigene testingMutation carriersMutation prevalencePopulation prevalenceExact testLimited prevalence dataGene mutationsLikely pathogenic mutationsFisher's exact testCancer risk genesClinical characteristicsGleason scoreMean ageClinical trialsPCa diagnosisFA genesFas gene mutationPrevalence ratesCancer managementPCa biologyFA pathway genes
2021
Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis
Loeb S, Massey P, Leader A, Thakker S, Falge E, Taneja S, Byrne N, Rose M, Joy M, Walter D, Katz M, Wong R, Selvan P, Keith S, Giri V. Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis. JMIR Cancer 2021, 7: e27063. PMID: 34542414, PMCID: PMC8550715, DOI: 10.2196/27063.Peer-Reviewed Original ResearchProstate cancerBreast cancerGenetic testingHereditary cancer riskBreast cancer contentGermline testingPCa managementCancer riskHealth professionalsBRCACancerBreastcancerCancer contentProstatecancerPublic awarenessPopulation awarenessSearch termsPrecision medicineSubset of tweetsTotal numberTestingGreater reachBRCA1/2Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs
Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly W, Calvaresi A, Handley N, Hirsch I, Izes J, Lallas C, Mann M, Mark J, Mille P, Preate D, Trabulsi E, Tsang M, Chandrasekar T, Weiner P, Gomella L, Giri V. Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs. JCO Precision Oncology 2021, 5: 1377-1386. PMID: 34589662, PMCID: PMC8462590, DOI: 10.1200/po.21.00238.Peer-Reviewed Original ResearchConceptsGermline testingProstate cancerGenetic counselingDecisional conflictComparable patient-reported outcomesHereditary cancer assessmentPatient-reported outcomesCancer genetics knowledgePCa diagnosisPractice settingsPrecision careCancer assessmentInformed consentCategorical variablesSubstantial proportionGenetic knowledgeSignificant differencesContinuous variablesHigh rateMenPractice needsDescriptive statisticsProstate oncologyOutcomesCounselingGenetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care
Mark J, McDougall C, Giri V. Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care. Urologic Clinics Of North America 2021, 48: 311-322. PMID: 34210487, DOI: 10.1016/j.ucl.2021.03.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGermline testingProstate cancerGenetic testing guidelinesFirst-line therapyCastration-resistant diseaseEarly-stage diseaseProstate cancer careHealth care providersGenetic test resultsPCA careCancer careCare providersScreening settingCancer implicationsPARP inhibitorsTesting guidelinesPossible roleDiseaseCareMenPractice strategiesOncologistsTestingTherapyCancerBarriers and facilitators of germline genetic evaluation for prostate cancer
Loeb S, Li R, Nolasco T, Byrne N, Cheng H, Becker D, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. The Prostate 2021, 81: 754-764. PMID: 34057231, DOI: 10.1002/pros.24172.Peer-Reviewed Original ResearchConceptsCoordination of careProstate cancerChronic Diseases frameworkGuideline-concordant careGermline testingMedical oncologistsPatient factorsPhysicians' knowledgePhysician educationRadiation oncologistsPractice settingsDisease frameworkThematic saturationGenetic counselingGenetic evaluationCareOncologistsRecent dataCancerConstant comparative methodInterview guidePhysiciansNumerous barriersQualitative studyInterview transcriptsBarriers and facilitators of germline genetic evaluation for prostate cancer.
Loeb S, Li R, Sanchez Nolasco T, Byrne N, Cheng H, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. Journal Of Clinical Oncology 2021, 39: 28-28. DOI: 10.1200/jco.2021.39.6_suppl.28.Peer-Reviewed Original ResearchCoordination of careProstate cancerGenetic testingChronic Diseases frameworkGuideline-concordant careGermline genetic testingMetastatic prostate cancerGenetic counselingGermline testingLocalized diseasePatient factorsMedical oncologistsTherapeutic optionsCancer screeningPhysicians' knowledgeCurrent guidelinesPhysician educationRecent approvalRadiation oncologistsPractice settingsCancerDisease frameworkThematic saturationProstate Cancer GeneticsGenetic evaluation